Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Jul
18
Today In Oncology
COVID-19 Boosters Offer Protection for Patients With Cancer
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
Classifying Pancreatic Cysts Using AI Models
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo